Work Package 1: GLIOTREAT

Project 1: Validation of the APOPTO-CELL modelling environment as a superior predictor of treatment responsiveness in newly diagnosed and recurrent GBM patients

Location: Royal College of Surgeons in Ireland

Principal Investigator: Dr Brona Murphy

Collaborators: Prof Markus Morrison (University of Stuttgart, Germany), Dr Verena Murphy (Cancer Trials Ireland)

Project 2: Development of a validated mathematical model to predict GBM responsiveness to the translationally relevant TRAIL-variant IZI1551

Location: University of Stuttgart, Germany

Principle Investigator: Prof Markus Morrison

Collaborators: Dr Brona Murphy (Royal College of Surgeons in Ireland), Dr Lothar Terfloth (In silico Biotechnology, Germany)

Project 3: Development and testing of a CNS-penetrating variant of the translationally relevant TRAIL-variant IZI1551

Location: University of Stuttgart, Germany

Principle Investigator: Prof Markus Morrison

Collaborators: Dr Thomas Schirrmann (YUMAB, Germany), Prof Annette Byrne (Royal College of Surgeons in Ireland)

Project 4: Pre-clinical interrogation of checkpoint inhibitor immunotherapy in GBM implementing ultrasound (US)-induced opening of the BBB

Location: ICM Institute for Brain and Spinal Cord, France

Principle Investigator: Dr Ahmed Idbaih

Collaborators: Prof Markus Morrison (University of Stuttgart, Germany), Racim Bouabdallah, MD (Bristol Myers Squibb, France), Frederic Sottilini (CarThera, France), Dr Maria Mancini (Champions Oncology, United States of America)

Project 5: Anti-angiogenic Immunotherapy as a new treatment paradigm for GBM molecular subtypes

Location: Royal College of Surgeons in Ireland (RCSI Dublin City Centre Campus)

Principle Investigator: Prof Annette Byrne, RCSI Dept of Physiology & Medical Physics

Collaborators: Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie (VIB) Leuven, Belgium), Dr Maria Mancini (Champions Oncology, Baltimore, USA)

Project 6: Investigating intratumoural GBM heterogeneity in the context of antiangiogenic immune therapies

Location: Vlaams Instituut voor Biotechnologie, Belgium

Principle Investigator: Prof Gabriele Bergers

Collaborators: Oncurious, Belgium

Project 7: Drug repurposing of available anti-cancer agents for precision therapy of GBM patients

Location: Erasmus University Rotterdam, The Netherlands

Principle Investigator: Dr Martine Lamfers

Collaborators: Prof Jochen Prehn (Royal College of Surgeons in Ireland), Mr Hennie Henrichs (Teva Pharmaceutical Industries, The Netherlands)

Project 8: Genomic biomarker driven approach to better identify GBM patient responders to SOC therapy

Location: Agilent Technologies, Belgium

Principle Investigator: Dr Jurgen del Favero

Collaborators: Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie, Belgium), Dr Ahmed Idbaih (ICM Institute for Brain and Spinal Cord, France